Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 16;192(10):4813–4820. doi: 10.4049/jimmunol.1303369

Figure 6. Assessment of C. rodentium-associated disease in EPS-treated mice lacking MyD88 in myeloid or epithelial cells.

Figure 6

Myeloid MyD88 KO and epithelial MyD88 KO mice were treated with EPS (EPS+) (i.p.) 1 day prior to infection with C. rodentium (Cr) and disease was assessed 10 dpi. Injection with PBS and EPS+ alone served as negative controls. Serum KC levels (A), colonic crypt height (B), and diarrhea (C) were used as disease markers. Results are averages from at least two independent experiments and a total of 2–5 mice were assessed for each group.

HHS Vulnerability Disclosure